Table 4 Univariate and multivariate analyses of risk factors for Ki-67 level in the training cohort
From: Correlation analysis of MR elastography and Ki-67 expression in intrahepatic cholangiocarcinoma
Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Odds ratio | p | Odds ratio | p | |
Sex | 3.844 (1.632–9.053) | 0.002* | … | … |
CA19-9 | 2.775 (1.205–6.391) | 0.016* | … | … |
Largest diameter | 0.948 (0.798–1.126) | 0.540 | … | … |
Tumor margin | 1.348 (0.556–3.270) | 0.509 | … | … |
Signal homogeneity | 1.024 (0.402–2.610) | 0.961 | … | … |
Arterial enhancement | … | … | … | … |
Globala | … | … | … | … |
Partial | 2.667 (0.237–30.066) | 0.427 | … | … |
Peripheral enhancement | 7.407 (0.788–69.632) | 0.08 | … | … |
Enhancement pattern | … | … | … | … |
Progressivea | … | … | … | … |
Persistent | 1.941 (0.194–19.461) | 0.573 | … | … |
Degressive-washout | 0.324 (0.076–1.384) | 0.128 | … | … |
APHE | 1.250 (0.480–3.258) | 0.648 | … | … |
Capsule | 2.500 (0.826–7.564) | 0.105 | … | … |
Targetoid appearance | 3.846 (1.382–10.705) | 0.010* | … | … |
Satellite nodules | 1.234 (0.513–2.970) | 0.639 | … | … |
Bile duct dilation | 1.405 (0.602–3.278) | 0.432 | … | … |
Liver capsule retraction | 1.048 (0.455–2.410) | 0.913 | … | … |
Hemorrhage in mass | 1.447 (0.195–10.728) | 0.718 | … | … |
Necrotic or cystic portion | 1.167 (0.504–2.705) | 0.718 | … | … |
Central scar | 1.145 (0.510–2.571) | 0.743 | … | … |
Central darkness on T2WI | 1.100 (0.489–2.476) | 0.818 | … | … |
Vessel invasion | 1.394 (0.527–3.685) | 0.503 | … | … |
Lymphadenectasis | 1.337 (0.592–3.023) | 0.485 | … | … |
Tumor ADC | 0.028 (0.004–0.208) | < 0.001* | 0.030 (0.002–0.476) | 0.013 |
Tumor stiffness | 1.640 (1.327–2.027) | < 0.001* | 1.669 (1.307–2.131) | < 0.001* |
Liver stiffness | 0.950 (0.694–1.299) | 0.747 | … | … |